Drug
Tusamitamab ravtansine
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(75%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
3
75%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 4 finished
Non-Completion Rate
100.0%
4 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Terminated(4)
Detailed Status
Terminated3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
terminated375%
withdrawn125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT04659603
terminatedphase_2
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
NCT05245071
terminatedphase_1
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
NCT05429762
withdrawnphase_2
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
NCT05703555
Clinical Trials (4)
Showing 4 of 4 trials
NCT04659603Phase 2
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
NCT05245071Phase 2
Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA
NCT05429762Phase 1
Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
NCT05703555Phase 2
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4